Wellbiotec Balance Sheet Health
Financial Health criteria checks 6/6
Wellbiotec has a total shareholder equity of ₩37.2B and total debt of ₩5.6B, which brings its debt-to-equity ratio to 15%. Its total assets and total liabilities are ₩60.2B and ₩23.0B respectively.
Key information
15.0%
Debt to equity ratio
₩5.60b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩21.38b |
| Equity | ₩37.22b |
| Total liabilities | ₩23.02b |
| Total assets | ₩60.24b |
Financial Position Analysis
Short Term Liabilities: A010600's short term assets (₩38.7B) exceed its short term liabilities (₩20.6B).
Long Term Liabilities: A010600's short term assets (₩38.7B) exceed its long term liabilities (₩2.5B).
Debt to Equity History and Analysis
Debt Level: A010600 has more cash than its total debt.
Reducing Debt: A010600's debt to equity ratio has reduced from 31.8% to 15% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A010600 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A010600 has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 21.3% each year.